

GGT-001, Pulmonary Arterial Hypertension AAV Gene Therapy

GluGene Therapeutics



CARDIOVASCULAR	Lead
Product Type	Recombinant adeno-associated viral (AAV) vector-based genetic therapeutics for the treatment of pulmonary arterial hypertension (PAH)
Indication	Pulmonary Arterial Hypertension (PAH)
Target	Pulmonary Arterial Smooth Muscle Cell (PASMC)
MoA(Mechanism of Action)	Restoration of aberrant phenotypic switch of PASMCs by delivering a regulatory gene to PASMCs
Competitiveness	AAV-based safe & efficient Gene therapy for the treatment of PAH (one-shot and done-therapy) Capsid engineering & novel regulatory gene
Development Stage	Lead
Route of Administration	Intratracheal injection